Additional early-stage research and drug discovery news in brief, from: CSL, Elicio Therapeutics, Enzolytics, Innovation Pharmaceuticals, Lumen Bioscience, Nanology.
Additional early-stage research and drug discovery news in brief, from: Applied DNA Sciences, Cardiol Therapeutics, SQZ Biotechnologies, Therapeutic Solutions International.
Infex Therapeutics Ltd. has divulged nonstructural protein 3 (nsp3, PL-PRO) macrodomain (Mac1) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Imunon Inc. has reported partial results from an ongoing nonhuman primate study designed to examine the immunogenicity of its proprietary Placcine vaccine (PL-COV). The data support Placcine as a viable alternative to mRNA vaccines.
Maxwell Biosciences Inc. has announced data on the utility of its Claromer drug discovery platform for the treatment and prevention of SARS-CoV-2, and potentially other respiratory viruses, through a series of preclinical in vitro and in vivo studies.
McMaster University has identified antibody-recruiting molecules (ARMs) consisting of human coronavirus (SARS-CoV-2) proteins targeting domain covalently bound to an antibody-binding terminus (recruiting anti-DNP antibodies) through a linker.
Immunoprecise Antibodies Ltd.'s subsidiary, Talem Therapeutics LLC, has shared promising results of a new study conducted by the National Institute of Allergy and Infectious Diseases (NIAID) showing continued resilience of Polytope TATX-03 in broadly neutralizing SARS-CoV-2 variants, including two omicron sublineages that had not been previously tested.
Invivyd Inc. (formerly Adagio Therapeutics Inc.) has generated multiple next-generation candidate antibodies for the prevention and treatment of COVID-19, including two molecules designated for near-term clinical development in combination as NVD-200.
RSS
